PE 22-28 Peptide
Category:
Neurocognitive health
PE22-28 is a specialized peptide fragment derived from spadin that modulates TREK-1 potassium channels. This targeted mechanism provides rapid-acting support for mood regulation, cognitive enhancement, and neuroprotection without typical side effects associated with conventional approaches. Clinical research suggests applications for depression, anxiety, and cognitive optimization through its unique neurological pathways.
Benefits of PE 22-28:
- Antidepressant effects: Studies suggest PE-22-28 has rapid antidepressant effects, potentially by upregulating neurogenesis and enhancing the firing rates of serotonin neurons. It has shown the ability to reduce depression-like behaviors. Some studies even indicate a faster onset of action compared to traditional antidepressants like SSRIs, and with potentially fewer side effects.
- Neurogenesis and Synaptogenesis: Research indicates that PE-22-28 can induce neurogenesis (the growth of new neurons) and synaptogenesis (the formation of new synapses) in the hippocampus, a brain region crucial for mood, memory, and learning. Studies in mice showed this effect after only four days of treatment.
- Cognitive Enhancement: Studies suggest PE-22-28 may improve cognitive function, including memory and learning abilities, potentially by enhancing synaptic plasticity and increasing levels of neurotrophic factors like BDNF. It has been shown to improve memory recall and may help mitigate age-related cognitive decline.
- Neuroprotection: PE-22-28 has demonstrated neuroprotective properties in various studies, including protecting neuronal cells from damage induced by oxidative stress and inhibiting neuronal apoptosis (programmed cell death). It may also help reduce neuroinflammation.
- Potential for Neurodegenerative Diseases: Research suggests that PE-22-28 could be beneficial in the context of neurodegenerative conditions like Alzheimer's disease, possibly by reducing neuronal loss, inhibiting amyloid plaque formation, and improving cognitive function.
- Stroke Recovery: Studies in models showed that treatment with a shorter analog of PE-22-28 improved post-stroke recovery by reducing immobility and increasing learning and motor coordination, potentially by increasing neurogenesis even weeks after the stroke.
- Anxiety Reduction: Some research indicates that PE-22-28 may have anxiolytic effects, reducing anxiety-like behaviors. It could potentially help stabilize mood and improve stress resilience.
- Muscle Function: Emerging research suggests PE-22-28, by inhibiting the TREK-1 receptor, might influence muscle contractility and relaxation, potentially offering avenues for research in understanding muscle physiology and conditions like myogenic bladder dysfunction.